United Therapeutics
UTHR
293 hedge funds and large institutions have $6.43B invested in United Therapeutics in 2013 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 115 increasing their positions, 109 reducing their positions, and 24 closing their positions.
38% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $8.63M
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
19% more capital invested
Capital invested by funds: $5.38B → $6.43B (+$1.05B)
2% more funds holding
Funds holding: 287 → 293 (+6)
6% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 109
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$24.2M |
| 2 |
JP Morgan Chase
New York
|
+$21.3M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$17.9M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$17.4M |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$94.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$21.1M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$15.5M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$12M |
| 5 |
Renaissance Technologies
New York
|
-$10.9M |
UTHR Hedge Fund Activity: Q3 2013 in Review
293 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2013, worth a combined $6.43B — up 19% from $5.38B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new UTHR positions and 24 closed out — a net gain of 9 holders — while 115 added to existing stakes and 109 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $24.2M. The largest seller was Wellington Management Group, cutting an estimated $94.4M.
- 293 institutional investors held United Therapeutics (UTHR) as of Q3 2013, up from 287 in Q2 2013.
- Funds reported $6.43B of United Therapeutics stock for Q3 2013, up 19% quarter-over-quarter.
- 33 funds opened new United Therapeutics positions in Q3 2013 and 24 closed out, a net change of +9 holders.
- The largest United Therapeutics buyer in Q3 2013 was First Trust Advisors, an estimated $24.2M added.
- The largest United Therapeutics seller in Q3 2013 was Wellington Management Group, an estimated $94.4M sold.
Based on aggregated 13F filings for Q3 2013.